Disclaimer: The animation in this presentation was produced before the FDA approval of dupilumab for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. February 24, 2026. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s075lbl.pdf)

PROGRAM CHAIR

Thomas B. Casale, MD, FAAAAI, FACAAI, FACP
Professor of Medicine and Pediatrics
Division of Allergy and Immunology
Department of Internal Medicine
Morsani College of Medicine
University of South Florida
Tampa, Florida

PROGRAM OVERVIEW

Welcome to this educational snapshot of type 2 inflammation (T2I), designed to expand the knowledge base of allergists, immunologists, and other clinicians who manage type 2 inflammatory conditions such as atopic dermatitis, COPD, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic esophagitis. In this program, the presenter will discuss the pathophysiology and interrelated pathways of the type 2 inflammatory response and how these may guide biomarker assessment and the selection of biologic therapies for T2I-related diseases. The program will also examine the importance of interdisciplinary care and referral systems in managing patients with multiple comorbid T2I-related diseases.

TARGET AUDIENCE

Allergists and immunologists who care for patients with type 2 inflammatory diseases.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Explain the rationale for biologics that target type 2 inflammation and how they disrupt mechanisms of disease in patients with type 2 inflammatory diseases
• Describe the criteria and tools for assessing disease severity, disease control, and type 2 inflammation biomarkers as well as criteria for making referrals for patients with type 2 inflammatory diseases
• Evaluate the clinical data, mechanisms of action, and indications for biologics that target type 2 inflammation as well as guideline recommendations for their clinical use for patients with type 2 inflammatory diseases

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.75 ANCC contact hours.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Carrie Allen, PharmD, BCPS, Medical Director for Med Learning Group has nothing to disclose.
• Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager for Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator for Med Learning Group, has nothing to disclose.
• Russie Allen, MM, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASED DATE: March 27, 2026
EXPIRATION DATE: March 27, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.